RXRX R&D Expenses
Recursion Pharmaceuticals Inc Clas · R&D Expenses
RXRX R&D Expenses
Latest reported$381.91Mperiod ending
RXRX TTM R&D Expenses ($63.32M → $381.91M)
TTM R&D Expenses
High-resolution chart · PNG
RXRX r&d expenses history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | R&D Expenses (USD) |
|---|---|
| 381,911,000 | |
| 420,933,000 | |
| 462,671,000 | |
| 477,666,000 | |
| 431,204,000 | |
| 376,496,000 | |
| 314,422,000 | |
| 285,570,000 | |
| 280,977,000 | |
| 262,109,000 | |
| 241,226,000 | |
| 215,724,000 | |
| 186,553,000 | |
| 169,932,000 | |
| 155,696,000 | |
| 160,008,000 | |
| 152,418,000 | |
| 143,603,000 | |
| 135,271,000 | |
| 107,677,000 | |
| 90,966,000 | |
| 74,586,000 | |
| 63,319,000 |